MRNA FCF Margin
Free cash flow as a percentage of revenue, showing how much of each sales dollar becomes cash.
FCF Margin
Latest: -388.3% (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | -71.9% |
| 2023Q2 | -334.0% |
| 2023Q3 | -95.0% |
| 2023Q4 | 14.3% |
| 2024Q1 | -709.6% |
| 2024Q2 | -604.1% |
| 2024Q3 | -92.2% |
| 2024Q4 | 31.4% |
| 2025Q1 | -1068.5% |
| 2025Q2 | -649.3% |
| 2025Q3 | -86.6% |
| 2025Q4 | 131.4% |
| 2026Q1 | -177.9% |
| 2026Q2 | -388.3% |
Other MRNA Charts
More quarter-by-quarter fundamentals for Moderna, Inc.
1 / 10
Revenue
EPS
Free Cash Flow
Gross Margin
P/E Ratio
Cumulative FCF
Shares Outstanding
Total Assets
Total Debt
Rule of 40
Healthcare Comparison
1 / 3
Latest FCF Margin: -388.3% (2026Q2); +261.0 pp YoY.
Across the 14 quarters from 2023Q1 to 2026Q2, FCF Margin ranged from -1068.5% in 2025Q1 to 131.4% in 2025Q4.